Van Andel Research Institute partners with CPT to accelerate development of new Parkinson’s treatments.

Grand Rapids, Michigan, USA (23rd September 2014)

Van Andel Research Institute (VARI) has partnered with UK-based research charity The Cure Parkinson’s Trust on an initiative to identify new treatments for Parkinson’s disease. The collaboration, called the Linked Clinical Trials (LCT) initiative, is aimed at repositioning medications approved to treat other diseases, which have also shown promise in slowing or reversing Parkinson’s in preclinical laboratory experiments. LCT could significantly cut down on the time and cost of moving new Parkinson’s treatments from the lab to clinical implementation. It also commits both organizations to ensuring the LCT initiative is adequately funded to achieve its ultimate aim of accelerating breakthroughs in Parkinson’s treatment.

LCT is founded on the idea that conducting smaller, more cost-effective trials with similar protocols, patients and outcomes allows scientists to see which repositioned drug is most effective, while also maximizing the number of trials conducted. Likewise, focusing on drugs that have already passed rigorous safety trials to treat other diseases significantly reduces the time and funding required to bring a potentially life-altering treatment to market. Traditional drug discovery has a less than 10 percent success rate, while studies have shown that repositioning drugs that have already passed Phase I safety and toxicology studies has an about 30 percent success rate across drugs used to treat a range of diseases. Currently, it can take more than a decade and can cost more than a billion dollars to move a drug from the lab, through trials, and on to patients. LCT aims to shorten that time frame.

“The Linked Clinical Trials Initiative is a novel approach to an exceedingly difficult problem,” said Dr. Patrik Brundin, chair of the LCT committee, associate director of research at VARI, and director of VARI’s Center for Neurodegenerative Science. “By targeting drugs that already are in use, we have the potential to create real, tangible change for patients on a much shorter timeline.” Large-scale Parkinson’s disease clinical trials are rare because of prohibitively high costs, and lack of reliable biomarkers and models for the disease. This prevents discoveries from moving forward and slows the development of therapies that could positively affect patient health.

The LCT committee is made up of some of the world’s leading Parkinson’s disease scientists and prioritizes existing drugs based on their potential to treat Parkinson’s. Drugs that make the shortlist are then fast tracked into Parkinson’s disease clinical trials. The committee has already narrowed down its initial list to several drugs that hold promise for Parkinson’s patients. One of these drugs, exenatide, is used to treat type 2 diabetes and currently is the subject of an ongoing Parkinson’s disease clinical trial at University College London. In a study published earlier this year in the Journal of Parkinson’s Disease, scientists at University College London showed that patients given exenatide were still doing better than the control group one year after the patients stopped taking the drug, suggesting that the drug can modify the course of the disease.

"As someone who is involved in the quest for a cure for Parkinson’s and has lived with the condition for the past 20 years, I am confident that the Linked Clinical Trials programme represents the most exciting opportunity to find a breakthrough in Parkinson’s research,” said Tom Isaacs, co-founder of The Cure Parkinson’s Trust. “LCT brings together the best science along with the funding, the clinical expertise, and the much needed engagement and influence of patients. The programme ensures there is a carefully planned development strategy for every drug prioritized by the LCT committee, which consists of many of the finest scientific minds in Parkinson’s research today. The fact that all the trials will be on treatments that already have proven safety profiles in other conditions inspires our belief that the LCT programme will quickly generate therapies for Parkinson’s that will at last have the capacity to stop or reverse this illness.”

Brundin and Isaacs signed a letter of intent (pictured above) during the annual Linked Clinical Trials committee meeting at VARI on 22nd September 2014. The collaboration is the culmination of a three-year long effort between VARI and The Cure Parkinson’s Trust to develop the LCT initiative. As part of the agreement, The Cure Parkinson’s Trust and VARI will contribute funding to the initiative.

Latest

For some considerable time CPT has been interested in nerve growth factors or 'neurotrophic' factors for Parkinson's. GDNF, CDNF and C-CDNF are three interesting candidates and our research work within this field continues with drive and urgency.

Dr. Johnny Acheson is an Emergency Medical Consultant who is also living with Parkinson’s. Johnny has created sketches to fundraise and to educate about Parkinson’s and depict the humorous side of working in emergency medicine!

Over 50 cyclists, including Mike Tindall and Iain Balshaw, will set off independently on 28 June to tackle what would have been the toughest day on the 'Raid Alpine' ride - but instead, they'll be doing this around their local area!

Related

CPT's President Tom Isaacs has used his networking powers to help engage a stellar list of renowned contemporary artists to create individual pieces of work to raise funds for The Cure Parkinson's Trust.

Naga Munchetty and James Haggar hosted the Batchworth Golf Club Foxes Invitation Meeting. James is presiding over his year of captaincy at the club and The Cure Parkinson's Trust is delighted to be his chosen beneficiary charity.

Researchers at Johns Hopkins have two important new clues in the fight against Parkinson's: blocking an enzyme prevents the disease in mice and a chemical tag on a second protein may signal the disorder's presence.

A postmortem examination of a patient with Parkinson's who underwent dopaminergic cell transplantation 24 years ago has shown that the transplanted neurons had reinnervated the brain for all that time.

On Sunday 24th April, CPT's team of dedicated runners hit the streets of London in support of our research. We can't thank them enough for their mammoth efforts over these past months and, of course, that huge feat yesterday!

Most read

In a major breakthrough for the treatment of Parkinson's, researchers working with laboratory rats show it is possible to make dopamine cells from embryonic stem cells and transplant them into the brain.

Our International Linked Clinical Trials initiative (iLCT) identifies potential new treatments to slow, stop or reverse Parkinson’s disease by 'repurposing' or repositioning drugs that are approved to treat other conditions.

The study, published in The Lancet and funded by The Michael J. Fox Foundation for Parkinson’s Research (MJFF), supported by CPT found that people with Parkinson’s treated with Exenatide for one year performed better in motor tests than those on placebo.

At this current time, we are working remotely and are unable to fulfill orders made via our online shop. We kindly ask that you refrain from purchasing items until normal working practices are resumed. Thank you for your patience. Please stay safe and well. From all at CPT.